NCT04242095
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
StatusRecruiting
PhaseNot specified
Primary completion (estimated)
At risk: Primary completion moved 12 months later.
See at-risk trials from Alliance for Clinical Trials in Oncology
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 55 versions: 50 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 1, 2026 to Oct 1, 2027
- Study sites: 629 to 630
- Minor Trial sites expanded: 625 → 629 locations
Notable Enrollment increased: 240 → 2240 participants Show 4 more changesShow less
- Eligibility criteria expanded, about 168 words
- Site details revised at 46 of 625 sites
- Study description shortened, about 2 words
- Study title expanded, about 3 words
- Minor Site contacts updated at 5 of 625 sitesv52
- Minor Study sites revised (625)v51
Show 45 earlier versionsHide 45 earlier versions
- Minor Study sites: 626 to 625v50
- Minor Study sites revised (626)v49
- Minor Study sites revised (626)v48
- Minor Study sites: 625 to 626v47
- Minor Site details revised at 1 of 625 sitesv46
- Minor Site details revised at 3 of 625 sitesv45
- Minor Study sites: 623 to 625v44
- Minor Study sites: 622 to 623v43
- Minor Study sites revised (622)v42
- Minor Study sites: 621 to 622v41
- Minor Study sites: 620 to 621v40
- Minor Study sites: 610 to 620v39
- Minor Study sites: 604 to 610v38
- Notable Primary and study completion dates: Oct 1, 2025 to Oct 1, 2026
- Start date: Jan 31, 2020 to Mar 12, 2020
- Site details revised at 485 of 604 sites
- Minor Study sites: 601 to 604v36
- Minor Study sites: 595 to 601v35
- Minor Study sites: 574 to 595v34
- Minor Study sites: 573 to 574v33
- Minor Study sites: 570 to 573v32
- Minor Study sites: 566 to 570v31
- Minor Study sites: 563 to 566v30
- Minor Study sites: 546 to 563v29
- Minor Study sites: 519 to 546v28
- Notable Primary and study completion dates pushed to Oct 1, 2025v27
- Minor Study sites revised (519)v26
- Minor Site details revised at 6 of 519 sitesv25
- Minor Study sites: 517 to 519v24
- Minor Study sites: 514 to 517v23
- Minor Study sites: 513 to 514v22
- Minor Study sites: 506 to 513v21
- Minor Study sites: 505 to 506v20
- Minor Study sites: 504 to 505v19
- Minor Study sites: 502 to 504v18
- Minor Study sites revised (502)v17
- Minor Study sites: 492 to 502v16
- Minor Study sites revised (492)v15
- Minor Study sites: 491 to 492v14
- Minor Study sites: 488 to 491v13
- Minor Study sites: 484 to 488v12
- Minor Study sites: 483 to 484v11
- Minor Study sites: 461 to 483v10
- Minor Study sites: 449 to 461v9
- Minor Study sites: 433 to 449v8
- Minor Study sites: 381 to 433v7
- Minor Study sites: 366 to 381v6
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Establishment of a national biorepository including biospecimen and clinical data collections for future use
Timeframe: Up to 1 year
Arms and interventions
Observational (biospecimen collection, medical record review)
Patients undergo collection of tissue and blood samples (and optional stool samples from patients experiencing colitis) at the time of registration (within 72 hours of confirmation of one or more severe irAEs) and at 1 month after registration. Patients' medical records are also reviewed for up to 1 year.
Procedures: Biospecimen Collection
Other: Medical Chart Review
Sites
630 sites in 1 country